Journal
CHEMICAL ENGINEERING JOURNAL
Volume 426, Issue -, Pages -Publisher
ELSEVIER SCIENCE SA
DOI: 10.1016/j.cej.2021.130838
Keywords
DNA repair inhibitor; Photosensitizer; Hybrid nanoassembly; Photodynamic therapy; Multimodal cancer treatment
Categories
Funding
- National Natural Science Foundation of China [81872816, 81773656]
- Excellent Youth Science Foundation of Liaoning Province [2020-YQ-06]
- Liaoning Revitalization Talents Program [XLYC1808017, XLYC1907129]
- China Postdoctoral Science Foundation [2020M670794]
- Science and Technology Major Project of Liaoning [2019JH1/10300004]
Ask authors/readers for more resources
This study presents a facile and practical dual-drug co-assembly engineering strategy, constructs an efficient and versatile co-delivery nanoplatform, and demonstrates significant combination anticancer efficacy in vitro and in vivo. The dual-drug hybrid nanoassembly shows potential as a promising nanomedicine for clinical multimodal cancer therapy.
Photodynamic therapy (PDT) has been extensively explored for cancer treatment. There is growing evidence showing that oxidative DNA damage caused by the vast accumulation of reactive oxygen species (ROS) in tumor cells plays a dominant role in accelerating cell apoptosis. Nevertheless, the repair pathways of aberrant DNA in tumor cells help reduce and reverse such damage. Thus, a precise combination of photodynamic photosensitizers and DNA repair inhibitors is expected to significantly augment the PDT efficacy. But it remains challenging to achieve accurate co-delivery of two drugs into the target sites. Herein, an ingenious dual-drug assembly modality is developed to precisely engineer a novel co-delivery nanomedicine. For proof-of-concept, a carrier-free hybrid nanoassembly of etoposide (VP-16) and pyropheophorbide a (PPa) is elaborately fabricated for multimodal DNA damage-mediated synergistic cancer therapy. Generally, this study exhibits a facile and practical dual-drug co assembly engineering strategy, constructs an efficient and versatile co-delivery nanoplatform, and enables significant combination anticancer efficacy in vitro and in vivo. Such a dual-drug hybrid nanoassembly has the potential to be utilized as a promising nanomedicine for clinical multimodal cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available